Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kumar, Shaji K., Hayman, Suzanne R., Buadi, Francis K., Roy, Vivek, Lacy, Martha Q., Gertz, Morie A., Allred, Jacob, Laumann, Kristina M., Bergsagel, Leif P., Dingli, David, Mikhael, Joseph R., Reeder, Craig B., Stewart, A. Keith, Zeldenrust, Steven R., Greipp, Philip R., Lust, John A., Fonseca, Rafael, Russell, Stephen J., Rajkumar, S. Vincent, Dispenzieri, Angela
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3418771/
https://ncbi.nlm.nih.gov/pubmed/22504925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-407791
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars